3-Aminopyrazolo[1,5-a]pyridine-2-carbonitrile | 1395491-79-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡唑并吡啶类
• 英文名称: 3-Aminopyrazolo[1,5-a]pyridine-2-carbonitrile
• 英文别名: 3-aminopyrazolo[1,5-a]pyridine-2-carbonitrile
• CAS: 1395491-79-8
• 化学式: C₈H₆N₄
• 分子量: 158.162
• InChiKey: GQSVJDLYWZCECD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  67.1
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-Aminopyrazolo[1,5-a]pyridine-2-carbonitrile 在 titanium(IV) isopropylate 、 2-甲基吡啶-N-甲硼烷 作用下， 以 四氢呋喃 、 甲醇 、 溶剂黄146 为溶剂， 反应 26.0h， 生成 3-[(cyclopropylmethyl)[(tetrahydro-2H-pyran-4-yl)methyl]-amino]pyrazolo[1,5-a]pyridine-2-carbonitrile
  参考文献：
  名称：

  Synthesis and Structure–Activity Relationships of Pyrazolo[1,5-a]pyridine Derivatives: Potent and Orally Active Antagonists of Corticotropin-Releasing Factor 1 Receptor

  摘要：

  Design, synthesis, and structure activity relationships of a series of 3-dialkylamino-7-phenyl pyrazolo[1,5-a]pyridines (I) as selective antagonists of the corticotropin-releasing factor 1 (CRF1) receptor are described. The most prominent compound to emerge from this work, 46 (E2508), exhibits potent in vitro activity, excellent drug-like properties, and robust oral efficacy in animal models of stress-related disorders. It has advanced into clinical trials.

  DOI：

  10.1021/jm300259r
• 作为产物：
  描述：

  2-(methylsulfonyl)-3-nitropyrazolo[1,5-a]pyridine 在 palladium 10% on activated carbon 、 氢气 作用下， 以 四氢呋喃 、 乙酸乙酯 、 N,N-二甲基甲酰胺 为溶剂， 20.0~80.0 ℃ 、101.33 kPa 条件下， 反应 8.0h， 生成 3-Aminopyrazolo[1,5-a]pyridine-2-carbonitrile
  参考文献：
  名称：

  Synthesis and Structure–Activity Relationships of Pyrazolo[1,5-a]pyridine Derivatives: Potent and Orally Active Antagonists of Corticotropin-Releasing Factor 1 Receptor

  摘要：

  Design, synthesis, and structure activity relationships of a series of 3-dialkylamino-7-phenyl pyrazolo[1,5-a]pyridines (I) as selective antagonists of the corticotropin-releasing factor 1 (CRF1) receptor are described. The most prominent compound to emerge from this work, 46 (E2508), exhibits potent in vitro activity, excellent drug-like properties, and robust oral efficacy in animal models of stress-related disorders. It has advanced into clinical trials.

  DOI：

  10.1021/jm300259r